MannKind

Yahoo Finance • 5 days ago

MannKind Appoints Dr. Ajay Ahuja as Executive Vice President and Chief Medical Officer

WESTLAKE VILLAGE, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for patients with endocri... Full story

Yahoo Finance • 29 days ago

MannKind's Plan of Increasing Revenue Base, Advancing Potential Pipeline Enhances its Value Creation, Oppenheimer Says

MannKind's (MNKD) game plan of enhancing its revenue base, while also advancing a potential pipeline PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • last month

There are notable gap-ups and gap-downs in today's session.

The session on Tuesday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TODAY'S GAP UP STOCKS TICKER CHANGE COMMENT CARM... Full story

Yahoo Finance • last month

Tuesday's pre-market session: top gainers and losers

Let's have a look at what is happening on the US markets before the opening bell on Tuesday. Below you can find the top gainers and losers in today's pre-market session. [premarket] PRE-MARKET GAINERS TICKER CHANGE COMMENT CA... Full story

Yahoo Finance • last month

Why MannKind (MNKD) Is Up 11.7% After Expanding Technosphere Partnership With United Therapeutics

On August 24, 2025, United Therapeutics announced an amendment to its license and collaboration agreement with MannKind, expanding the deal to cover a new development product formulated using MannKind’s Technosphere platform and triggering... Full story

Yahoo Finance • last month

MannKind Corporation (MNKD) Seeks FDA Pediatric Approval for Afrezza

We recently published 10 Best Biotech Stocks to Buy Under $10.MannKind Corporation stands fifth among them. MannKind Corporation (NASDAQ:MNKD) is a biopharmaceutical company developing inhaled therapeutic products for endocrine and orphan... Full story

Yahoo Finance • last month

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: scPharmaceuticals Inc. (Nasdaq – SCPH), Vital Energy, Inc. (NYSE – VTLE), International Money Express, Inc. (Nasdaq - IMXI), HanesBrands Financial Corp. (NYSE - HBI)

BALA CYNWYD, Pa., Aug. 28, 2025 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ack... Full story

Yahoo Finance • last month

MannKind to Present at Upcoming Investor Conferences

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of innovative inhaled therapeutic products and devices for pat... Full story

Yahoo Finance • last month

MannKind rises as United Therapeutics exercises option for second inhalational drug

[Collaboration concept. Colored threads are connected together and the inscription.] designer491/iStock via Getty Images * MannKind Corporation (NASDAQ:MNKD [https://seekingalpha.com/symbol/MNKD]) added ~10% in the morning hours on Wedn... Full story

Yahoo Finance • last month

MannKind Announces Expansion of United Therapeutics Collaboration for Second Inhaled Therapy

DANBURY, Conn. and BOSTON, Aug. 27, 2025 (GLOBE NEWSWIRE) --  MannKind Corporation (Nasdaq: MNKD) today announced that United Therapeutics Corporation (Nasdaq: UTHR) has exercised its option—granted under the companies’ 2018 license and... Full story

Yahoo Finance • last month

MannKind stock price target raised to $8 by RBC on scPharmaceuticals deal

Investing.com - RBC Capital raised its price target on MannKind (NASDAQ:MNKD) to $8.00 from $7.00 on Tuesday, while maintaining an Outperform rating following the company’s acquisition of scPharmaceuticals (NASDAQ:SCPH). InvestingPro data... Full story

Yahoo Finance • last month

Leerink Partners Reiterates a Buy Rating on MannKind Corporation (MNKD), Keeps the PT at $7

MannKind Corporation (NASDAQ:MNKD) is one of the top strong buy stocks under $5 to buy now. On August 8, Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on MannKind Corporation (NASDAQ:MNKD), keeping the price target at $7... Full story

Yahoo Finance • last month

MannKind to Acquire scPharmaceuticals, Accelerating Revenue Growth and Emerging as a Patient-Centric Leader in Cardiometabolic and Lung Diseases

Acquisition expected to diversify and accelerate double-digit revenue growth with FUROSCIX®, an innovative treatment for edema due to chronic heart failure and chronic kidney disease, addressing significant unmet needUpfront cash payment o... Full story

Yahoo Finance • 2 months ago

MannKind (MNKD) Secures $500M Financing to Advance Inhaled Therapies Pipeline

We recently published 12 Best Healthcare Stocks to Buy Under $30. MannKind Corporation (NASDAQ:MNKD) is one of the best healthcare stocks. MannKind Corporation (NASDAQ:MNKD)’s most recent milestone is its push to expand the use of its rap... Full story

Yahoo Finance • 2 months ago

MannKind Corp (NASDAQ:MNKD) Q2 2025 Earnings Miss Estimates, Shares Drop 3.8% in Pre-Market

MannKind Corp (NASDAQ:MNKD [https://www.chartmill.com/stock/quote/MNKD]) reported its second-quarter 2025 financial results, missing analyst expectations on both revenue and earnings per share (EPS). The company posted revenue of $76.53 mi... Full story

Yahoo Finance • 2 months ago

MannKind Non-GAAP EPS of $0.05 misses by $0.03, revenue of $76.53M misses by $2.25M

* MannKind press release [https://seekingalpha.com/pr/20190756-mannkind-corporation-reports-second-quarter-2025-financial-results-and-provides-business] (NASDAQ:MNKD [https://seekingalpha.com/symbol/MNKD]): Q2 Non-GAAP EPS of $0.05 misse... Full story

Yahoo Finance • 2 months ago

MannKind and Blackstone Announce up to $500 Million Strategic Financing Agreement

Strengthens MannKind’s capital structure with flexible, long-term, non-dilutive fundingMannKind to receive $75 million in cash at closing DANBURY, Conn. and WESTLAKE VILLAGE, Calif. and NEW YORK, Aug. 06, 2025 (GLOBE NEWSWIRE) -- MannKi... Full story

Yahoo Finance • 2 months ago

MannKind Corporation Reports Second Quarter 2025 Financial Results And Provides Business Update

2Q 2025 revenues of $76.5M, +6% v. 2Q 2024YTD 2025 revenues of $154.9M, +12% v. YTD 2024Advanced pipeline: Submitted sBLA for Afrezza® in pediatric populationMNKD-101: NTM global Phase 3 trial (ICoN-1) enrollment ahead of scheduleMNKD-201... Full story

Yahoo Finance • 2 months ago

MannKind Corporation to Hold 2025 Second Quarter Financial Results Conference Call on August 6, 2025

DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- MannKind Corporation (Nasdaq: MNKD), announced today that its second quarter 2025 financial results will be released before market open on August 6, 2025. Ma... Full story

Yahoo Finance • 2 months ago

MannKind Corporation (MNKD) Presented Inhaled Insulin Therapy At American Diabetes Association

MannKind Corporation (NASDAQ:MNKD) is one of the Best American Penny Stocks to Buy According to Analysts. MannKind Corporation (NASDAQ:MNKD) presented inhaled insulin therapy at the American Diabetes Association’s 85th Scientific Sessions... Full story